Arium

Genetic Analysis

GA Service Laboratory

Your front-end solution to microbiota profiling



10 years of expertise in microbiota analysis

We facilitate your research with GA-map® technology

Genetic Analysis (GA) has developed a CE-marked probe based gut microbiota test. The technology uses single nucleotide differences in the 16S rRNA gene to identify predetermined targets at different taxonomic levels. Due to our proprietary probe based hybridization technology, the test is reproducible, fast and easy to interpret. The test has gone through thorough clinical validation[1].

Interpretation of results

With the GA-map® technology, the need for comprehensive calculations in microbiota research is removed. The results are presented in an easy to read report form with abundance of 48 preselected bacteria markers (figure 1). These bacteria have proved to be of high importance for gut health in the literature and through extensive laboratory testing[1]. Normalized data for all markers are provided and raw data can be provided upon request.



Reference population comparison

The bacteria abundance is compared to our normal reference population. The GA-map® analyser software algorithm calculates the degree of dysbiosis in the samples.

Service laboratory

GA has a service laboratory in Oslo, Norway which can analyse cohorts of clinical studies as well as patient samples. We can organize shipment, analysis and reporting of results.



Figure 1 Advanced bacteria analysis is presented in an easy to read report form. In addition, normalized data for all markers are provided for research use.

Reproducible

The performance of the GA-map® technology has been well documented through extensive verification and validation[1]. The standardisation and documentation of the GA-map® test ensures highly reproducible results.

ISO certified and CE-marked

Quality is important in gut microbiota analysis. GA as a company achieved an ISO 13485:2016 certification in June 2018 covering both development and manufacturing. The GA-map® Dysbiosis Test is CE-marked in Europe. GA-map™ IMT is available for research use in the US.

Clinically validated

The GA-map® test has been validated as described[1] using cohorts of healthy volunteers, IBS and IBD patients. In addition the test has been used in a number of clinical studies on numerous patient cohorts published in peer reviewed journals[2–5]. Hence, the GA-map® platform represents the next step of gut microbiota diagnostics and multicenter studies.

1. Casén et al 2015. Aliment Parmacol Ther. 42(1):71-83
2. Bennet et al 2012. Gut. 0:1-10
3. Magnusson et al 2016. J Crohns Colitis. 10(8):943-52
4. Valeur et al 2018. Dig Dis Sci.
5. Andréasson et al 2016. Arthritis Research & Therapy 18:278;

MAR18-009-1

We facilitate your microbiota research with GA-map® technology in 3 fast and simple steps:

1) Shipping of Samples

Shipping samples across borders can be challenging. GA will make sure that the valuable samples are safely transported.

2) Samples Analysis



Using the proprietary patented GA-map® Dysbiosis Test, by performing **S**ingle **nu**cleotide **p**rimer **e**xtension (SNuPE) in the 16S rRNA gene.

3) Bioinformatics



Results:
- Result report form
- Dysbiosis Index
- Normalized data

Normal lead time: From 2 weeks

Genetic Analysis

Arium
COMMITTED TO INNOVATION

Phone: +351 21 795 69 12
www.arium.pt | info@arium.pt